Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT00403039 Completed - Clinical trials for Retinal Vein Occlusion

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema

NCT ID: NCT00403026 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Intravitreal Bevacizumab for Retinal Disorders

Start date: August 2006
Phase: N/A
Study type: Interventional

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

NCT ID: NCT00401115 Completed - Clinical trials for Diabetic Retinopathy

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Start date: September 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy

NCT ID: NCT00387582 Completed - Clinical trials for Diabetic Retinopathy

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Start date: July 2006
Phase: Phase 2
Study type: Interventional

This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.

NCT ID: NCT00379795 Completed - Clinical trials for Choroidal Neovascularization, Age-related Macular Degeneration

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Start date: April 2005
Phase: N/A
Study type: Interventional

This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort enrolled patients with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). The results of the second cohort are reported separately (NCT01442064). The first cohort of this study enrolled two subsets of patients: ranibizumab experienced and ranibizumab-naive. Patients were enrolled within 14 days of completion of the 24 month treatment phase of the previous study.

NCT ID: NCT00371410 Completed - Clinical trials for Diabetic Macular Edema

Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema

Start date: April 2005
Phase: Phase 1
Study type: Interventional

Macular edema constitutes the primary cause of visual impairment in diabetic patients with a disease duration of 20 years or more. Intravitreal triamcinolone (IVTA) and macular focal laser photocoagulation were reported to generate favorable results in the treatment of diabetic macular edema, but there have been patients with diffuse diabetic macular edema refractory to such treatment modalities. The present study will test the safety and the efficacy of the combined treatment of vitrectomy, IVTA and macular focal laser photocoagulation in the treatment of intractable diffuse diabetic macular edema.

NCT ID: NCT00371111 Active, not recruiting - Clinical trials for Resistant Cystoid Macular Edema

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

Start date: August 2006
Phase: Phase 1
Study type: Interventional

Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

NCT ID: NCT00370669 Recruiting - Clinical trials for Diabetic Macular Edema

Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

Start date: November 2005
Phase: Phase 3
Study type: Interventional

to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)

NCT ID: NCT00370422 Active, not recruiting - Clinical trials for Diabetic Macular Edema

Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.

NCT ID: NCT00369863 Completed - Clinical trials for Diabetic Macular Edema

A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema

Start date: June 2002
Phase: Phase 2
Study type: Interventional

To determine the efficacy and safety of intravitreal triamcinolone acetonide for refractory diabetic macular edema.